

Special Issue

Genetic Advances in Neuromuscular Disorders: From Gene Identification to Gene Therapy

Message from the Guest Editors

We would like to invite you to participate in this Special Issue, “Genetic Advances in Neuromuscular Disorders: From Gene Identification to Gene Therapy”. More than 500 different disorders are included under the definition of neuromuscular disorders, and most of them are inherited diseases. In addition, these entities present a high clinical and genetic heterogeneity; in many cases, mutations in a single gene may be the cause of one or more neuromuscular disorders, while some disorders can be attributed to mutations in several genes. An ongoing revolution in diagnostic techniques has identified a large number of causative genes in the last two decades, and treatments are now being developed against these new targets. The purpose of this Special Issue is to host research and review papers on our molecular understanding of neuromuscular disorders and associated genetic therapies. New results, confirmatory results, and contradictory results will also be considered for publication.

Guest Editors

Prof. Dr. Virginia Arechavala-Gomeza

1. Neuromuscular Disorders Group, Biocruces Bizkaia Health Research Institute, Barakaldo, Spain
2. Ikerbasque, Basque Foundation for Science, Bilbao, Spain

Dr. Lidia Gonzalez-Quereda

CIBERER, IIB Sant Pau, 08025 Barcelona, Spain

Deadline for manuscript submissions

closed (31 October 2020)

G C A T
T A C G
G C A T

Genes

an Open Access Journal
by MDPI

Impact Factor 2.8
CiteScore 5.5
Indexed in PubMed



mdpi.com/si/30061

Genes
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
genes@mdpi.com

[mdpi.com/journal/
genes](https://mdpi.com/journal/genes)



G C A T
T A C G
G C A T

Genes

an Open Access Journal
by MDPI

Impact Factor 2.8
CiteScore 5.5
Indexed in PubMed



[mdpi.com/journal/
genes](https://mdpi.com/journal/genes)



About the Journal

Message from the Editor-in-Chief

Genes is central to our understanding of biology, and modern advances such as genomics and genome editing have maintained genetics as a vibrant, diverse and fast-moving field. There is a need for good quality, open access journals in this area, and the *Genes* team aims to provide expert manuscript handling, serious peer review, and rapid publication across the whole discipline of genetics. Starting in 2010, the journal is now well established and recognised. Why not consider *Genes* for your next genetics paper?

Editor-in-Chief

Prof. Dr. Selvarangan Ponnazhagan
Experimental Cancer Therapeutics, The University of Alabama at
Birmingham, 1825 University Blvd., SHEL 814, Birmingham, AL 35294-
2182, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, PubAg, and other databases.

Journal Rank:

JCR - Q2 (Genetics and Heredity) / CiteScore - Q2 (Genetics (clinical))